Goldman Sachs' recent list of eight "disruptive technologies" included new therapies to fight cancer, drugs that promise to upend the pharma industry in the next few decades. Most promising is immunotheraphy, an approach being researched and advanced by Bristol-Myers (NYSE:BMY), Merck (NYSE:MRK), and Roche (Nasdaq:RHHBY), among others. While these drugs aren't cancer cures, they appear to be on pace to deliver significant improvements in the length of time cancer patients can expect to live, with a relatively tolerable side-effects.
 
Virtually any drug that can meaningfully extend the life of patients with melanoma, breast, or lung cancer is likely to generate over $1 billion in revenue per year, as investors can see in sell-side research estimates or through back-of-the-envelope calculations. There are about 25,000 cases of advanced melanoma in the U.S. and European Union each year, more than 70,000 cases of advanced breast cancer, and over 125,000 cases of lung cancer. Oncology drugs with demonstrated efficacy advantages have increasingly been securing reimbursement of close to (and above) $100,000 on the basis of course of treatment. 

SEE: Evaluating Pharmaceutical Companies

Immunotherapy is just one new approach to fighting cancer, but it alone could ultimately encompass vaccines, oncolytic viruses, and adoptive t-cell technologies, creating a market of $25 billion to $40 billion by the end of the next decade. Those estimates are based on the current size of the market and the potential for immunotherapy to gain as much as a 50% share of the oncology market. The basic mechanics of the therapies involve bringing down the “shield” that hides a cancer cell from the immune system – allowing the immune system to see it as a foreign body and attack it. On the stimulation side, it appears possible to actually increase the anti-tumor activity of the patient's own T-cells, basically upgrading their weaponry for fighting cancerous cells
 
Immuno-Oncology Coming Into View As A Real Opportunity
It wasn't until the 1990's that immunology began to be explored as a way to treat cancer. Early results then weren't great, as tumor responses were pretty modest and toxicity with patients was a real problem. Recently, though, the approach has started looking significantly better.
 
From the approval of Bristol-Myers' Yervoy drug for melanoma (in March of 2011) to Dendreon's (Nasdaq:DNDN) Provenge, immunotherapy (broadly defined, at any rate), has emerged as real treatment option and a major new area of focus in the oncology space. While Provenge has proven to be a disappointment, Yervoy is already annualizing to $1 billion in revenue, and the low end of sell-side revenue expectations for Roche's new drug Kadcyla is already at about $1 billion within just a few years.  As of now, it looks as though the approach could deliver multiple multi-billion dollar blockbusters for the pharmaceutical industry by 2018, while also meaningfully extending the lives of patients with particular types of cancer.
 
SEE:  Pharmaceutical Phenoms: America's Best-Selling Medicines 

Early Leaders In Place
Bristol-Myers, Merck, and Roche have emerged as early leaders in immunotherapy with anti-PD-1/PD-L1 agents (compounds that "unmask" cancer cells and expose them to attack from the patient's immune system) that appear efficacious in treating melanoma, non-small cell lung cancer, and renal carcinoma. These drugs have already shown very encouraging improvements in response rates and survival and analysts are suggesting approval over the next three to four years with sales potential upwards of $7 billion a year (each) at the peak.
 
These therapies represent significant growth opportunities for both Bristol-Myers and Merck. For Roche, though, it's more complicated. As Roche already enjoys a very large oncology franchise (due to the success of biologics like Avastin), there is more of an element of the company protecting what it already has, though that only applies to this first generation of compounds. On the other hand, if these new immunotherapy agents work synergisticly with existing drugs (and you can bet there will be trials exploring that), it could create an even greater opportunity for the company.
 
Plenty Of Others Can Play A Role
While Bristol-Myers, Merck, and Roche have arguably the most advanced portfolios of immunotherapy agents, AstraZeneca (NYSE:AZN) also has a credible portfolio of early checkpoint-based immunotherapy approaches, and Glaxo (NYSE:GSK) has both an early-stage checkpoint immunotherapy and a therapeutic vaccine. Novartis (NYSE:NVS) has interesting research in the cell therapy side, while Incyte's (Nasdaq:INCY) small molecule IDO inhibitor is also worth watching.
 
Beyond this are a host of drugs in pre-clinical or very early stage human studies at a variety of small biotechs. Assuming that no major safety issues appear in the late-stage trials of the anti-PD-1/PD-L1 approaches, it seems safe to assume that a wave of in-licensing and acquisitions will occur as Big Pharma players with weak immunotherapy portfolios look to strengthen their hand.
 
The Bottom Line
It's very, very early, but immunotherapy holds a great deal of promise to improve the treatment of cancer and the lives of those who have it. Immunotherapy won't offer cures, but meaningful survival benefits coupled with tolerable side-effect profiles could make this the dominant approach to fighting cancer in 2020 and a market worth over $25 billion.
 
All of that said, some perspective is in order. Bristol-Myers is small enough that a single blockbuster could be transformative, but the impact is likely to be smaller at companies like Merck and Roche. So while success with immunotherapy is certainly part of the bullish thesis for all three of these companies, it is only a part of a more complicated investment perspective.
 
Disclosure – At the time of writing, the author owned shares of Roche

Related Articles
  1. Investing

    Build a Retirement Portfolio for a Different World

    When it comes to retirement rules of thumb, the financial industry is experiencing new guidelines and the new rules for navigating retirement.
  2. Mutual Funds & ETFs

    ETF Analysis: Direxion Daily Healthcare Bull 3X

    Learn about the Direxion Daily Healthcare Bull. This is a leveraged ETF that tracks the health care sector, which is a leader in this bull market.
  3. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  4. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  5. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  6. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  8. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  9. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  10. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!